As the current respiratory syncytial virus (RSV) season ends, most infants are protected against this severe disease.
According to the U.S. CDC's MMWR ( 74(16);273–281) published on May 8, 2025, in the first RSV season with widespread availability of maternal vaccine and long-acting monoclonal antibody, RSV-associated hospitalization rates among infants were lower than in prepandemic seasons.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
